Che-Kai Tsao

Kai Tsao, MD MS is the System Chief of Solid Tumor, Medical Director of Zuckerberg Cancer Center and Medical Oncology Prostate Cancer Program at the Northwell Health Cancer Institute. He is a disciple of cancer quality and LEAN process improvement, using outcome and metric-driven approach in driving innovative and patient centered care.

He completed medical school at SUNY Downstate, Internal medicine residency at LIJ AECOM, and fellowship Hematology and Medical Oncology at Mount Sinai Hospital, where he served as the chief fellow. He was honored as Mount Sinai Hospital Physician of the year Fellow award in 2012, and recipient of the 2023 TCI Solid Tumor Faculty Teacher of the Year award. He previously served as the medical director of Ruttenberg Treatment Center, Prostate cancer medical oncology program, and Mount sinai international collaborations. He completed a Green belt Lean Six Sigma course at John Hopkins University in 2017. He completed a Masters of Healthcare Delivery Leadership at the Icahn School of Medicine at Mount Sinai in 2020. Since 2016, he has led several important collaborations on behalf of Mount Sinai international, and has helped several international partners to develop hospitals and international centers of excellence.

To date, he has authored more than 180 peer reviewed publications, abstracts, and text books in the field of genitourinary oncology. His main focus is on development of novel therapies in the treatment of genitourinary cancers. Additionally, his other focus is to define the relationship of clinical and molecular phenotypes in advanced prostate and kidney cancers

Dr. Atish Choudhury is Senior Physician within the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School. He received a BA in Chemistry from Johns Hopkins University and dual MD/PhD degrees from Columbia University, where he studied the BRCA1 and BARD1 tumor suppressor genes in the laboratory of Dr. Richard Baer. He completed his residency in internal medicine at Brigham and Women's Hospital and medical oncology fellowship at Dana-Farber Cancer Institute, where he studied genes responsible for conferring castration resistance in prostate cancer models in the laboratory of Dr. William Hahn and collaborated with the blood biopsy team at the Broad Institute of MIT and Harvard on genetic profiling from circulating tumor cells and circulating cell-free DNA from prostate cancer patients. Dr. Choudhury currently serves as chair of the Gelb Center for Translational Research and co-director of the Prostate Cancer Center at Dana-Farber/Brigham and Women’s Cancer Center. His primary research interests are related to clinical investigation into novel treatments for advanced prostate cancer and accompanying biomarker studies from tissue and blood specimens to understand mediators of response and resistance to therapy.